SCHEMBL14025564

SCHEMBL14025564

CC(c1ccccc1)N(C)S(=O)(=O)c1cccc(CNCc2ccccc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 1/20 0.48
NAMPT P43490 1/20 0.47
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
TNF P01375 1/20 0.42
NOD1 Q9Y239 1/20 0.42
POLB P06746 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
CA2 P00918 2/20 0.40
CA1 P00915 1/20 0.40
BCHE P06276 2/20 0.39
NMT1 P30419 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.39
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14025550 0.88 ALDH1A1 (0.48) ALDH1A1KDM4ENAMPTMEN1KMT2A
SCHEMBL14025567 0.79 HTT (0.53) ALDH1A1KDM4ENAMPTPOLBCYP2C9
SCHEMBL11432868 0.79 CCR5 (0.50) ALDH1A1KDM4ENAMPTMEN1KMT2A
SCHEMBL14025560 0.79 ALDH1A1 (0.53) ALDH1A1KDM4ENAMPTMEN1KMT2A
SCHEMBL14025584 0.76 NR1H2 (0.49) ALDH1A1KDM4E
SCHEMBL14068043 0.73 MEN1 (0.44) ALDH1A1KDM4EMEN1KMT2ANPC1
SCHEMBL14025570 0.73 CASP3 (0.49) ALDH1A1KDM4EMEN1KMT2ANPC1
SCHEMBL12956598 0.71 BCHE (0.56) ALDH1A1KDM4EMEN1KMT2ABCHE
SCHEMBL14025561 0.70 KEAP1 (0.71) ALDH1A1RAB9ACYP1A2CA2CA1
SCHEMBL14025593 0.69 TAS2R14 (0.55) MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed
WO-2008109154-A1 CHEMOKINE RECEPTOR MODULATORS ALTIRIS THERAPEUTICS, INC. (US) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea MKI67, CCNI, CDKN1A ALDH1A1 423/4885KDM4E 532/4885NAMPT 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.